Product nameAnti-Integrin alpha V beta 3 antibody [BV3]
See all Integrin alpha V beta 3 primary antibodies
DescriptionMouse monoclonal [BV3] to Integrin alpha V beta 3
SpecificityThis monoclonal antibody binds to human CD51 and Cd61 integrins present on human endothelium cells.
Tested applicationsSuitable for: ICC/IF, IHC-P, IHC-Fr, IP, Flow Cytmore details
Unsuitable for: WB
Species reactivityReacts with: Rat, Chicken, Human
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.1% Sodium azide
Constituent: 0.2% BSA
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab7166 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
RelevanceFunction: The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). (Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for adenovirus type C (PubMed:20615244). Integrin ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for coxsackievirus A9 and B1 (PubMed:9426447, PubMed:15194773, PubMed:7519807). Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB6 acts as a receptor for herpes simplex 1/HHV-1 (PubMed:24367260). Integrin ITGAV:ITGB3 acts as a receptor for Human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for West nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733). Similarity: Belongs to the integrin alpha chain family. Contains 7 FG-GAP repeats.
Cellular localizationCell Membrane. Cytoplasmic. Integrin complex. Focal adhesion.
- Antigen identified by monoclonal antibody L230 antibody
- CD 51 antibody
- CD 61 antibody
ab7166 staining human breast cancer cells by ICC/IF. Cells were paraformaldehyde fixed for 10 minutes and blocked in 5% serum for 1 hour at 25°C. The primary antibody was diluted 1/250 and incubated with the sample for 16 hours. An Alexa Fluor® 488 conjugated goat polyclonal to mouse antibody, diluted 1/200 was used as the secondary.
ab7166 staining Integrin alpha V beta 3 in human MeWo melanoma cells by Flow Cytometery. Cells were cultured in 24 well plates and harvested with 100 µL trypsin/ EDTA. Cells were fixed in 1:1 mixture of FACS/Flow and 4% paraformaldehyde in PBS. The primary antibody was diluted to 1 µg/ml and incubated with sample in 3% bovine serum albumin in phosphate buffer for 30 minutes at 37°C. An ab6785, FITC-conjugated goat polyclonal to mouse IgG (1/100) was used as secondary. A459 cells were used as negative control and showed no significant binding of the antibody. Different concentrations were evaluated and 1 µg/ml yield gave the best results. Blank cells were not treated with any antibodies at all, sec only cells were treated with secondary but not primary antibody.
This product has been referenced in:
- Ma R et al. Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis. Sci Rep 7:4978 (2017). Read more (PubMed: 28694452) »
- Park SH et al. RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy. Theranostics 6:1672-82 (2016). IF . Read more (PubMed: 27446500) »